How Does a Physician Avoid Prescribing Drugs and Medical Procedures That Have Reproductive and Developmental Risks?

Clinics in Perinatology

Volumn 34, Issue 2, 2007, Pages 233-262

  Brent, Robert L ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPTERIN; AMINOSALICYLIC ACID; ANDROGEN; ANTIDEPRESSANT AGENT; CAFFEINE; COBALT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIETHYLSTILBESTROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GESTAGEN; INSULIN; ISONIAZID; ISOTRETINOIN; LEFLUNOMIDE; LITHIUM; METHOTREXATE; METHYLENE BLUE; MINOXIDIL; MISOPROSTOL; PENICILLAMINE; PROPYLTHIOURACIL; RADIOISOTOPE; RETINOIC ACID; RETINOID; SEROTONIN UPTAKE INHIBITOR; THIAMAZOLE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ANURIA; AORTA ARCH ANOMALY; BIRTH DEFECT; CENTRAL NERVOUS SYSTEM MALFORMATION; CLEFT PALATE; CONGENITAL HEART DISEASE; CONGENITAL HEART MALFORMATION; CUTIS LAXA; EAR MALFORMATION; EBSTEIN ANOMALY; EXPERT WITNESS; FETUS; FETUS HYPOTENSION SYNDROME; FETUS MALFORMATION; GENITAL MALFORMATION; GOITER; GROWTH RETARDATION; HEMOLYTIC ANEMIA; HIRSUTISM; HUMAN; HYDROCEPHALUS; HYPOTENSION; INTESTINE ATRESIA; JAUNDICE; JOINT HYPERMOBILITY; LATHYRISM; LAW SUIT; LIMB REDUCTION DEFECT; LUNG HYPOPLASIA; MALPRACTICE; MEDICAL LIABILITY; MEDICAL PRACTICE; MEDICOLEGAL ASPECT; MENINGOMYELOCELE; MENTAL DEFICIENCY; MICROCEPHALY; MICROTIA; MOEBIUS SYNDROME; NEWBORN; OLIGOHYDRAMNIOS; PHYSICIAN; PREGNANT WOMAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SKIN APLASIA; THYMUS APLASIA; THYROID DYSGENESIS; UNITED STATES; VAGINA ADENOSIS; VIRILIZATION;

ABNORMALITIES; COUNSELING; FEMALE; HUMANS; HYPERTENSION; LIABILITY, LEGAL; MALPRACTICE; MENTAL DISORDERS; MORNING SICKNESS; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS; PREGNANCY; RADIATION INJURIES; TERATOGENS;

EID: 34250218201     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2007.03.003     Document Type: Review

References (82)

1. Brent R.L. Medicolegal aspects of teratology. J Pediatr 71 (1967) 288-298
2. Fraser F.C. Causes of congenital malformations in humans. J Chronic Dis 10 (1959) 97-110
3. Wilson J.G. Factors involved in causing congenital malformations. Bull N Y Acad Med 16 (1960) 145
4. Warkany J., and Kalter H. Congenital malformations. N Engl J Med 265 (1961) 993, 1046
5. Karnofsky D.A. Drugs as teratogens in animals and man. Ann Rev Pharmacol 5 (1965) 447-472
6. Mellin G.W. Drugs in the first trimester of pregnancy and fetal life of Homo sapiens. Am J Obst Gynecol 90 (1964) 1169-1180
7. Wilson J.G. Environment and birth defects (1973), Academic Press, New York
8. Brent RL, Harris M. The prevention of embryonic fetal and perinatal disease; Bethesda (MD), US Govt. Publication DHEW Publ. NIH 76-853. 1975. p. 411.
9. Beckman D.A., and Brent R.L. Fetal effects of prescribed and self-administered drugs during the second and third trimester. In: Avery G.B., Fletcher M.A., and MacDonald M.G. (Eds). Neonatology: pathophysiology and treatment. 4th edition (1994), JB Lippincott Company, Philadelphia 197-206
10. Brent R.L., and Beckman D.A. Prescribed drugs, therapeutic agents, and fetal teratogenesis. In: Reece E.A., and Hobbins J.C. (Eds). Medicine of the fetus and mother. 2nd edition (1999), Lippincott-Raven Publishers, Philadelphia 289-313
11. Brent RL. Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Pediatrics 2004;113(4):957-68.
12. Warkany J. Congenital malformation: notes and comments (1971), Year Book Medical Publishers, Chicago
13. Warkany J. Congenital malformations in the past. J Chronic Dis 10 (1959) 84-95
14. Warkany J., and Kalter H. Maternal impressions and congenital malformations. Plast Reconstr Surg 30 (1962) 628-637
15. Headley C.J. Records of the colony and plantation of New Haven from 1638 to 1649 (1857), Case Tiffany & Co, Hartford (CT)
16. Landauer W. Hybridization between animals and man as a cause of congenital malformations. Extra Arch Anat Histol Embryol Normales et Exper 14 Suppl (1961) 155-168
17. Sinkler appellant, v Kneale, 401 Pa., Appeal No. 124, January 1960, from order of the Court of Common Pleas of Chester County, March 1, 1959. No. 49, of Sinkler v Kneale, 1960; 267-78.
18. Lejeune J., Turpin R., and Gauteir M. Le mongolisme, maladie chromosomique (trisomie). Bull Acad Nat Med 143 (1959) 256-265
19. Patau K., Smith D.W., Therman E., et al. Multiple congenital anomaly caused by an extra autosome. Lancet 9 (1960) 790-793
20. Makino S. Chromosomal studies in normal human subjects in 300 cases of congenital disorders. Int J Cytol 9 1 (1964) 13-31
21. Caroll v Skloff 159: In the Supreme Court of Pennsylvania, Eastern District No. 131, January 1, 1964. Appeal from the Judgment of the Court of Common Pleas No. 1 of Philadelphia County, March Term, 1963, No. 5407, sustaining appellees' preliminary objections and dismissing appellants' complaint, Entered October 25, 1963.
22. Churchill J. Rights of the fetus to sue. Br Med J (1973) 224
23. Brent R.L. The irresponsible expert witness: a failure of biomedical graduate education and professional accountability. Pediatrics 70 (1982) 754-762
24. Physician Insurers Association of America. Available at: http://www.piaa.us/about_piaa/what_is_piaa.htm.
25. Brent R.L. Litigation-produced pain, disease and suffering: an experience with congenital malformation lawsuits. Teratology 16 (1977) 1-14
26. Beckman D.A., Fawcett L.B., and Brent R.L. Developmental toxicity. In: Massaro E.J. (Ed). Handbook of human toxicology (1997), CRC Press, New York 1007-1084
27. Brent R.L. Non-genital malformations following exposure to progestational drugs: the final chapter of an erroneous allegation. Birth Defects, Part A 73 11 (2005) 906-918
28. Gal I., Kirman B., and Stern J. Hormonal pregnancy tests and congenital malformations. Nature 216 (1967) 83
29. Janerich D.T., Piper J.M., and Glebatis D.M. Oral contraceptives and congenital limb-reduction defects. N Engl J Med 291 14 (1974) 697-700
30. Levy E.P., Cohen A., and Fraser F.C. Hormone treatment during pregnancy and congenital heart. Lancet 1 (1973) 611
31. Heinonen O.P., Sloane D., Monson R.R., et al. Cardiovascular birth defects and antenatal exposure to female sex hormones. N Eng J Med 296 (1977) 67-70
32. Heinonen O.P., Slone D., and Shapiro S. Birth defects and drugs in pregnancy (1977), Publishing Sciences Group Inc, Littleton (MA) p. 126-48
33. Nora J.J., and Nora A.H. Preliminary evidence for a possible association between oral contraceptives and birth defects. Teratology 7 (1973) A24
34. Nora J.J., and Nora A.H. Birth defects and oral contraceptives. Lancet 1 (1973) 941-942
35. Nora J.J., Nora A.H., Perinchief A.G., et al. Congenital abnormalities and first-trimester exposure to progestogen/estrogen. Lancet 1 (1976) 313-314
36. Nora A.H., and Nora J.J. A syndrome of multiple congenital anomalies associated with teratogenic exposure. Arch Environ Health 30 (1975) 17-21
37. Nora J.J., Nora A.H., Blu J., et al. Exogenous progestogen and estrogen implicated in birth defects. JAMA 240 (1978) 837-843
38. Brent R.L. Kudos to the Food and Drug Administration: reversal of the package insert warning for birth defects for oral contraceptives. Teratology 39 1 (1989) 93-94
39. Food and Drug Administration. Progestational drug products for human use; requirements for labeling directed to the patient. Federal Register, Vol. 64, No. 70, Proposed Rules, Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA), 21 CFR Part 310, [Docket No. 99N-0188], 64 FR 17985, Date: Tuesday, April 13, 1999.
40. Wilson J.G., and Brent R.L. Are female sex hormones teratogenic?. Am J Obstet Gynecol 141 5 (1981) 567-580
41. Nocke W. Sind weibliche sexualsteroide teratogen? Ruckblick-Zwischenbilanz-Konsequenzen. Gynakologe 11 (1978) 119-141 [in German]
42. Are sex steroids teratogenic?. [editorial]. Lancet l (1974) 1489-1490
43. Holmes L.B. Teratogen update: bendectin. Teratology 27 2 (1983) 277-281
44. Brent RL. The bendectin saga: another American tragedy (Brent, '80). Teratology 27 (1983) 283-286
45. Brent R.L. Bendectin and interventricular septal defects. [editorial]. Teratology 32 (1985) 317-318
46. Brent R.L. Teratogen update: bendectin. [editorial comments]. Teratology 31 (1985) 429-430
47. Lasagna L., and Shulman S.R. Bendectin and the language of causation. In: Foster K.R., Bernsyein D.E., and Huber P.W. (Eds). Phantom risk: scientific interference and the law (1993), MIT Press, Cambridge (MA) 101-122
48. Brent R.L. Commentary: bringing scholarship to the courtroom: the Daubert decision and its impact on the Teratology Society. Teratology 52 (1995) 247-251
49. Brent R.L. Bendectin: review of the medical literature of a comprehensively studied human non-teratogen and the most prevalent tortogen-litigen. Reprod Toxicol 9 4 (1995) 337-349
50. Brent R.L. Review of the scientific literature pertaining to the reproductive toxicity of bendectin. In: Faigman D.L., Kaye D.H., Saks M.J., et al. (Eds). Modern scientific evidence: the law and science of expert testimony. vol. 2 (1997), West Publishing Group, St. Paul (MN) 373-393
51. Brent R.L. Medical, social and legal implications of treating nausea and vomiting of pregnancy. Am J Obstet Gynecol 186 5 (2002) S262-S266
52. Kutcher J.S., Engle A., Firth J., et al. Bendectin and birth defects. II: ecological analyses. Birth Defects Res A Clin Mol Teratol 67 2 (2003) 88-97
53. Brent R.L. Commentary on bendectin and birth defects: hopefully, the final chapter. Birth Defects Res A Clin Mol Teratol 67 2 (2003) 79-87
54. Skolnick A. Key witness against morning sickness drug faces scientific fraud charges. JAMA 283 (1990) 1466-1469
55. Hanson J.W., and Smith D.W. The fetal hydantoin syndrome. Teratology 11 2 (1975) 20A
56. OMIM, Online Mendelian inheritance in man. Available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM. Accessed October 12, 2006.
57. Friedman J.M., and Polifka J.E. TERIS. The teratogen information system (1999), University of Washington, Seattle (WA)
58. In: Scialli A.R., Lione A., and Padget G.K.B. (Eds). Reproductive effects of chemical, physical and biologic agents: Reprotox (1995), The Johns Hopkins University Press, Baltimore (MD)
59. In: Sever J.L., and Brent R.L. (Eds). Teratogen update: environmentally induced birth defect risks (1986), Alan R. Liss, New York 1-248
60. Shepard T.H. Catalogue of teratogenic agents. 8th edition (1995), The Johns Hopkins University Press, Baltimore (MD)
61. Schardein J.L. Chemically induced birth defects. 3rd edition (2000), Marcel Dekker, Inc., New York
62. Briggs G.G., Freeman R.K., and Yaffe S.J. Drugs in pregnancy and lactation. 3rd edition (1990), Williams and Wilkins, Baltimore (MD) p. 502-8
63. Brent RL. Utilization of developmental basic science principles in the evaluation of reproductive risks from pre- and postconception environmental radiation exposures. Presented at the thirty-third annual meeting of the National Council on Radiation Protection and Measurements. The Effects of Pre- and Postconception Exposure to Radiation. Arlington (VA), April 2-3, 1997. Teratology 1999;59:182-204.
64. Brent R.L., and Holmes L.B. Clinical and basic science lessons from the thalidomide tragedy: what have we learned about the causes of limb defects?. Teratology 38 (1988) 241-251
65. Brent R.L. Methods of evaluating the alleged teratogenicity of environmental agents. In: Sever J.L., and Brent R.L. (Eds). Teratogen update: environmentally induced birth defect risks (1986), Alan R. Liss, New York 199-201
66. Brent R.L. Improving the quality of expert witness testimony. Pediatrics 82 (1988) 511-513
67. Brent RL, Koren G, Scialli A, et al. Report on the safety of bendectin/Diclectin for use in the management of nausea and vomiting of pregnancy. Ottawa, Canada: Health Protection Branch; 1989.
68. Food and Drug Administration. Department of Health and Human Services. Determination that bendectin was not withdrawn from sale for reasons of safety or effectiveness. Docket nos. 92F and 97)-G437. 64 Federal Register 43190-1; 1999.
69. Brent R.L., and Beckman D.A. Angiotensin converting enzyme inhibitors: an embryopathic class of drugs with unique properties: information for clinical teratology counselors. Teratology 43 (1991) 543-546
70. Barr M. Teratogen update: angiotensin converting enzyme inhibitors. Teratology 50 (1994) 399-409
71. Al-Shabanah O.A., Al-Harbi M.M., AlGharably N.M.A., et al. The effect of maternal administration of captopril on fetal development in the rat. Res Commun Chem Pathol Pharmacol 73 (1994) 221-230
72. Alwan S., Polifka J., and Friedman J.M. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 73 (2005) 123-130
73. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. New Engl J Med 354 (2006) 2443-2451
74. Kallen B., and Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 21 (2006) 221-222
75. Diav-Citrin O., Shechtman S., Weinbaum D., et al. Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Reprod Toxicol 20 3 (2005) 459
76. Kulin N.A., Pastuszak A., Sage S.R., et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. A prospective controlled multicenter study. JAMA 279 8 (1998) 609-610
77. Rosa F. New medical entities widely used in fertile women: postmarketing surveillance priorities. Reprod Toxicol 9 6 (1995) 583
78. Brent RL, Jones CG, Roessler GS. Internet communications with the public: a new powerful health physics society tool. Presented at the eleventh International Congress of the International Radiation Protection Association. Madrid (Spain), May 23-28, 2004. Available at: http://www.irpa11.com. Accessed June 6, 2004.
79. Jones C.G., Roessler G.S., and Brent R.L. Effective radiological communications with the public. Strahlenschutz Praxis 4 (2004) 23-27
80. Brent R.L. Counseling patients exposed to ionizing radiation during pregnancy. Rev Panam Salud Publica 20 (2006) 198-205
81. Brent R.L. Microwaves and ultrasound. In: Queenan J.T., Hobbins J.C., and Spong C.Y. (Eds). Protocols high-risk pregnancy: a contemporary OB/GYN. 4th edition (2005), Blackwell Publishing, Malden (MA) 39-44
82. Brent RL. Malpractice experience and issues. In: Medical-legal issues in pediatrics, report of the eighteenth Ross roundtable on critical approaches to common pediatric problems in collaboration with the Ambulatory Pediatric Association. Columbus (OH): Ross Laboratories; 1987. p. 20-5.